Alembic Pharma Q3: Revenue Jumps 11%, Margins Stable; India, US Markets Drive Growth

• Alembic Pharmaceuticals reported a 10.8% year-on-year revenue increase to ₹1,876.3 crore in Q3, driven by strong domestic and international performance.
• EBITDA grew 12.8% to ₹293.5 crore, with margins slightly improving to 15.6% from 15.4% compared to the previous year.
• Net profit declined 4.1% to ₹132 crore due to a ₹42 crore one-time provision for employee benefits under new labour codes.
• India branded business grew 6% to ₹652 crore, led by gynaecology, ophthalmology, and animal healthcare, with four new product launches.
• US generics revenue rose 6% to ₹553 crore with two new launches, while ex-US international generics surged 36% to ₹406 crore; company received seven ANDA approvals.